Original Article: The Medical News http://bit.ly/2vtn9T2
AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Original Article: The Medical News http://bit.ly/2vtn9T2
>>Hollywood's Exotic Secret For Healthy Weight Loss
Original Article: The Medical News http://bit.ly/2vtn9T2
Subscribe to:
Post Comments (Atom)
0 Response to "AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma"
Post a Comment